Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108091
Title:
Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
Authors:
Thatcher, Nick; Palmer, Michael K; Gasiunas, Nijole; Crowther, Derek
Abstract:
Thirty-eight patients with metastatic melanoma were investigated for lymphocyte function immediately prior to chemo-immunotherapy. The pre-treatment immune tests were compared with normal control values and with response to therapy. The "non-responder" group (but not "responder") had significantly reduced values for lymphocyte, null-cell and E-rosette-cell counts compared with controls. Lymphocytoxicity ( using a Chang target cell) showed the same pattern, with depression of direct and K-cell cytotoxic capacity in non-responders compared with controls. Eight patients were studied sequentially whilst on treatment, and demonstrated considerable change (not statistically significant) in lymphocytotoxicity, an untreated "control" patient showed little variation. "Recall"-antigen skin testing showed no statistically significant difference between the patient groups. The data indicate that "non-T-cell activity" may be associated with response to chemo-immunotherapy.
Affiliation:
Cancer Research Campaign Department of Medical Oncology of Manchester University.
Citation:
Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. 1977, 36 (6):751-62 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Dec-1977
URI:
http://hdl.handle.net/10541/108091
PubMed ID:
597473
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorPalmer, Michael Ken
dc.contributor.authorGasiunas, Nijoleen
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-07-21T14:56:32Z-
dc.date.available2010-07-21T14:56:32Z-
dc.date.issued1977-12-
dc.identifier.citationLymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. 1977, 36 (6):751-62 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid597473-
dc.identifier.urihttp://hdl.handle.net/10541/108091-
dc.description.abstractThirty-eight patients with metastatic melanoma were investigated for lymphocyte function immediately prior to chemo-immunotherapy. The pre-treatment immune tests were compared with normal control values and with response to therapy. The "non-responder" group (but not "responder") had significantly reduced values for lymphocyte, null-cell and E-rosette-cell counts compared with controls. Lymphocytoxicity ( using a Chang target cell) showed the same pattern, with depression of direct and K-cell cytotoxic capacity in non-responders compared with controls. Eight patients were studied sequentially whilst on treatment, and demonstrated considerable change (not statistically significant) in lymphocytotoxicity, an untreated "control" patient showed little variation. "Recall"-antigen skin testing showed no statistically significant difference between the patient groups. The data indicate that "non-T-cell activity" may be associated with response to chemo-immunotherapy.en
dc.language.isoenen
dc.subjectCancer Metastasisen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshBCG Vaccine-
dc.subject.meshCytotoxicity, Immunologic-
dc.subject.meshDacarbazine-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLeukocyte Count-
dc.subject.meshLymphocytes-
dc.subject.meshMale-
dc.subject.meshMelanoma-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshRosette Formation-
dc.titleLymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Medical Oncology of Manchester University.en
dc.identifier.journalBritish Journal of Canceren
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.